EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• FebboPGLadanyiMAldapeKDNCCN Task Force report: evaluating the clinical utility of tumor markers in oncologyJ Natl Compr Canc Netw20119Suppl 5S1S32
   PubMed Web of Science ®Google Scholar
• KeedyVLTeminSSomerfieldMRAmerican Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyJ Clin Oncol201129152121212721482992
   PubMed Web of Science ®Google Scholar
• PirkerRHerthFJKerrKMEuropean EGFR Workshop GroupConsensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopJ Thorac Oncol20105101706171320871269
   PubMedGoogle Scholar
• AnguloBCondeESuárez-GauthierAA comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistryPLoS One201278e4384222952784
   PubMed Web of Science ®Google Scholar
• GotoKSatouchiMIshiiGAn evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic settingAnn Oncol201223112914291922776705
   PubMed Web of Science ®Google Scholar
• BakkerEIs the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessedClin Chem200652455755816595822
   PubMed Web of Science ®Google Scholar
• MarchettiAFelicioniLButtittaFAssessing EGFR mutationsN Engl J Med2006354552652816452569
   PubMed Web of Science ®Google Scholar
• QueringsSAltmullerJAnsénSBenchmarking of mutation diagnostics in clinical lung cancer specimensPLoS One201165e1960121573178
   PubMed Web of Science ®Google Scholar
• ValléeALe LouppAGDenisMGEfficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomasClin Chim Acta201442981124269715
   PubMed Web of Science ®Google Scholar
• da Cunha SantosGSaiegMAGeddieWLeighlNEGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunitiesCancer Cytopathol20111192809121400669
   PubMed Web of Science ®Google Scholar
• EllisonGZhuGMoulisADeardenSSpeakeGMcCormackREGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesJ Clin Pathol2013662798923172555
   PubMed Web of Science ®Google Scholar
• HagiwaraKKobayashiKImportance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancerCancer Sci2013104329129723240603
   PubMed Web of Science ®Google Scholar
• YungTKChanKCMokTSTongJToKFLoYMSingle-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patientsClin Cancer Res20091562076208419276259
   PubMed Web of Science ®Google Scholar
• DouillardJYOstorosGCoboMFirst-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm studyBr J Cancer20141101556224263064
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCSpanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• Fernández-RubioARuano-RaviñaACribado de Cáncer de Pulmón. Lung cancer screening [Report of Health Technology Assessment]. Ministerio de Ciencia e Innovación in Spanish [Spanish Ministry of Science and Innovation]. Available from: http://avalia-t.sergas.es/DXerais/289/avalia-t200706Cribado-ca-Pulmon.pdfAccessed December 23, 2015 Spanish
   Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• EstebanEMajemMMartinez AguilloMPrevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON studyCancer Epidemiol201539329129725766256
   PubMed Web of Science ®Google Scholar
• GarridoPde CastroJConchaÁGuidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)Clin Transl Oncol201214533834922551539
   PubMed Web of Science ®Google Scholar
• BaiHMaoLWangHSEpidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancerJ Clin Oncol200927162653265919414683
   PubMed Web of Science ®Google Scholar
• GotoKIchinoseYOheYEpidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancerJ Thorac Oncol20127111512121900837
   PubMed Web of Science ®Google Scholar
• KimuraHKasaharaKKawaishiMDetection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerClin Cancer Res200612133915392116818687
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMNorth-East Japan Study GroupUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar